QN-302 is under clinical development by Qualigen Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QN-302 overview
QN-302 is under development for the treatment of solid tumors such as pancreatic ductal adenocarcinoma (PDAC), sarcomas, prostate cancer, metastatic colorectal cancer and gastrointestinal stromal tumor (GIST). It acts by targeting genomic quadruplex (G4). It is administered through intravenous route.
Qualigen Therapeutics overview
Qualigen Therapeutics (Qualigen) develops therapeutics for the treatment of cancer and infectious diseases. The company’s cancer therapeutics pipeline includes QN-247 and RAS-F. QN-247 is a (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen is headquartered in Los Angeles, California, the US.
For a complete picture of QN-302’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
